ReviewNature2024
Sophisticated natural products as antibiotics.
Review in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed.
- Predicting resistance evolution to guide antibiotic development.Nature reviews. Microbiology · 2026Review
- A fungal-derived benzothiazole derivative overcomes osimertinib resistance in NSCLC by targeting SCD1.Natural products and bioprospecting · 2026Article
- Ocotea odorifera extract: antimicrobial and antibiofilm activities, phytochemical aspects, cytotoxicity and anti-inflammatory potential of an endangered plant species.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- ABPs: diffusible antibacterial toxins secreted by and active against diverse gram-positive bacteria.Infection and immunity · 2026Review
- Complete Genome Sequencing of Streptomyces sp. Qhu-M197 Isolated from Alpine Meadows in the Qinghai-Tibetan Plateau Uncovers Biosynthetic Gene Clusters Encoding Bioactive Natural Products.Biochemical genetics · 2026Article
- Self-resistance as a guide to discovering bioactive natural products.Current opinion in chemical biology · 2026Review
- ROS-Balancing MXene/MoSeSmall (Weinheim an der Bergstrasse, Germany) · 2026Article
- Versatile Targeted Celastrol Nanoassemblies for Enhanced Immunomodulatory Effects Against MRSA Infection.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- A Machine Learning-Based Genome Mining Approach Reveals Unprecedented Biarylitide Diversity.JACS Au · 2026Article
- Dual Silencing of Aminoglycoside Biosynthesis for the Discovery of Novel Antimicrobials in Streptomyces.Microbial biotechnology · 2026Article
- Understanding the Role of Macrocycle Size and Amide Linkage in Teixobactin Analogues.Biomolecules · 2026Article
- Medicinal Plants: A Promising Therapeutic Approach for Addressing Antimicrobial Resistance.International journal of molecular sciences · 2026Review
- Zwitterionic Penicillin-Derived Sulfone Inhibitor for Combating β-Lactamase-Mediated Antibiotic Resistance.ChemMedChem · 2026Article
- Inhibitors of cytochromemBio · 2026Article
- Molecular action of NZ2114, a superior plectasin derivative.npj antimicrobials and resistance · 2026Article
- Article
- The Extreme Environment Microbiome Catalog (EEMC): a global resource for microbial diversity and antimicrobial discovery.Nature communications · 2026Article
- Climate change propels antibiotic resistance from soils into hospitals.Nature microbiology · 2026Article
- EnvZ/OmpR-driven cooperative behavior promotes cefiderocol resistance in a hanging-droplet evolution system.Science advances · 2026Article
- New Chemical Scaffold with Antimicrobial Activity Identified in a Screening of Industrial Photoactive Compounds.Antibiotics (Basel, Switzerland) · 2026Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
In this Review, we explore natural product antibiotics that do more than simply inhibit an active site of an essential enzyme. We review these compounds to provide inspiration for the design of much-needed new antibacterial agents, and examine the complex mechanisms that have evolved to effectively target bacteria, including covalent binders, inhibitors of resistance, compounds that utilize self-promoted entry, those that evade resistance, prodrugs, target corrupters, inhibitors of 'undruggable' targets, compounds that form supramolecular complexes, and selective membrane-acting agents. These are exemplified by β-lactams that bind covalently to inhibit transpeptidases and β-lactamases, siderophore chimeras that hijack import mechanisms to smuggle antibiotics into the cell, compounds that are activated by bacterial enzymes to produce reactive molecules, and antibiotics such as aminoglycosides that corrupt, rather than merely inhibit, their targets. Some of these mechanisms are highly sophisticated, such as the preformed β-strands of darobactins that target the undruggable β-barrel chaperone BamA, or teixobactin, which binds to a precursor of peptidoglycan and then forms a supramolecular structure that damages the membrane, impeding the emergence of resistance. Many of the compounds exhibit more than one notable feature, such as resistance evasion and target corruption. Understanding the surprising complexity of the best antimicrobial compounds provides a roadmap for developing novel compounds to address the antimicrobial resistance crisis by mining for new natural products and inspiring us to design similarly sophisticated antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.